AstraZeneca
Compare AstraZeneca…UK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AstraZenecaUK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
SEC filings for this company are not available at the moment.